Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | PARG | Q86W56 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24176204 | 0.94 | MAP4K4 (0.33) | MET | |
| SCHEMBL24175707 | 0.93 | NPC1 (0.34) | METNPC1MEN1KMT2ARAB9A | |
| SCHEMBL24176009 | 0.91 | PARG (0.30) | PARG | |
| SCHEMBL24175783 | 0.89 | — | — | |
| SCHEMBL24165272 | 0.86 | NPC1 (0.34) | NPC1 | |
| SCHEMBL24165291 | 0.83 | NPC1 (0.31) | NPC1PARG | |
| SCHEMBL24175781 | 0.82 | PARG (0.30) | PARG | |
| SCHEMBL24175714 | 0.81 | CHRNB2 (0.32) | — | |
| SCHEMBL24176072 | 0.80 | USP30 (0.33) | PARG | |
| SCHEMBL24176070 | 0.78 | CSF1R (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767323-B2 | Tricyclic pyridone compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2023-09-26 | — | — | US | disclosed |
| US-20220002299-A1 | TRICYCLIC PYRIDONE COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION | 2022-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002299-A1 | TRICYCLIC PYRIDONE COMPOUNDS AS JAK2 V617F INHIBITORS | JAK2, JAK1, JAK3 | MET 1748/4885NPC1 4805/4885MEN1 3123/4885 |
| US-11767323-B2 | Tricyclic pyridone compounds as JAK2 V617F inhibitors | JAK2, JAK1, JAK3 | MET 1748/4885NPC1 4805/4885MEN1 3123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.